Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True
A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to
POSTER: Clinical Validation of an Image Analysis Assay for Determining Programmed Death-Ligand 1 (22C3) in Non-small Cell Lung Cancer
POSTER: Clinical Validation of an Image Analysis Assay for Determining Programmed Death-Ligand 1 (22C3) in Non-small Cell Lung Cancer Background: Determination of programmed death-ligand 1
POSTER: Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in
Evaluating Benefits of PD-L1 Image Analysis for the Clinical Setting
Key takeaways Our spatial biology approach using Flagship’s unique analysis technology reduced variability in tissue scoring Compared to manual scoring, ourAI-driven scoring of non-small cell
Recent Posts
- Flagship Biosciences Is Honored with a Best Practices Award
- A Digital Assay to Streamline PD-L1 IHC: Published in Scientific Reports
- Recognizing women leaders in biotechnology
- Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
- Tissue Based Companion Diagnostics in a Regulated Space
